Replies to post #124130 on Biotech Values

[DewDiligence]

3Q11 Yervoy sales were $121M, of which $109M was in the US:

http://finance.yahoo.com/news/BristolMyers-Squibb-Delivers-bw-1217874273.html?x=0&.v=1

The $121M was up from $95M in 2Q11 (Yervoy’s first quarter on the market), and the QoQ increase would have been higher if BMY had not deferred $27M of sales due to its new return policy.

60% of Yervoy use in 3Q11 was in the first-line setting (up from 40% during 2Q11).